type here...

CATEGORIES

Clinical Trials

LATEST

123Page 3 of 3

TRENDING

EDITORS CHOICE

Health Possibilities We Can’t Afford to Block

Gil Bashe, Medika Life Editor -
Fixing one piece of the healthcare puzzle is encouraging - but is it transformational? Here are 10 things we can consider to make things better.

Hepion Pharmaceuticals’ CRV431 Demonstrates Efficacy in Kidney Fibrosis

Medika Life -
CRV431 has exerted antifibrotic activity in a number of in vitro and in vivo studies conducted by independent research laboratories

Colchicine Shows 48% Reduction in Future Cardio Issues for Heart Attack Victims

Medika Life -
Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular problems by 48% in people who have just survived a heart attack

First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial

Medika Life -
The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and F3 NASH patients

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories